Replimune Group, Inc. (REPL): Price and Financial Metrics


Replimune Group, Inc. (REPL): $18.92

-0.32 (-1.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

REPL Stock Price Chart Interactive Chart >

Price chart for REPL

REPL Price/Volume Stats

Current price $18.92 52-week high $29.52
Prev. close $19.24 52-week low $13.05
Day low $18.82 Volume 860,400
Day high $19.58 Avg. volume 586,742
50-day MA $23.64 Dividend yield N/A
200-day MA $20.90 Market Cap 1.07B

Replimune Group, Inc. (REPL) Company Bio


Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.


REPL Latest News Stream


Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream


Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Barclays Global Healthcare ConferenceDate: Wednesday, March 15, 2023Fireside Chat Time: 2:05 pm EDTLocation: The Loews Miami Beach Hotel, Miam

Yahoo | March 8, 2023

Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | February 24, 2023

Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable

Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Yahoo | February 9, 2023

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be announced in Q3 2023 along with updates from ongoing RP1 skin cancer cohorts including anti-PD1 failed non-melanoma skin cancer (CSCC predominant) and the RP1 monotherap

Yahoo | February 9, 2023

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET. A simultaneous webcast will be available in the Investors section of Repl

Yahoo | February 7, 2023

Read More 'REPL' Stories Here

REPL Price Returns

1-mo -11.30%
3-mo -31.87%
6-mo 9.55%
1-year 13.50%
3-year 91.69%
5-year N/A
YTD -30.44%
2022 0.37%
2021 -28.96%
2020 165.85%
2019 43.50%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7128 seconds.